Publicaciones en colaboración con investigadores/as de Universidad Rey Juan Carlos (19)

2024

  1. DNA Methylation Levels of the ACE2 Promoter Are Not Associated with Post-COVID-19 Symptoms in Individuals Who Had Been Hospitalized Due to COVID-19

    Microorganisms, Vol. 12, Núm. 7

  2. Inflammatory Polymorphisms (IL-6 rs1800796, IL-10 rs1800896, TNF-α rs1800629, and IFITM3 rs12252) Are Not Associated with Post-COVID Symptoms in Previously Hospitalized COVID-19 Survivors

    Viruses, Vol. 16, Núm. 2

  3. Is Antiviral Treatment with Remdesivir at the Acute Phase of SARS-CoV-2 Infection Effective for Decreasing the Risk of Long-Lasting Post-COVID Symptoms?

    Viruses, Vol. 16, Núm. 6

  4. Post-COVID-19 Pain Is Not Associated with DNA Methylation Levels of the ACE2 Promoter in COVID-19 Survivors Hospitalized Due to SARS-CoV-2 Infection

    Biomedicines, Vol. 12, Núm. 8

2022

  1. Effectiveness of an HIV care model integrated into addiction care based on medication-assisted treatment for HIV-positive people who use drugs

    AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, Vol. 34, Núm. 10, pp. 1297-1304

  2. Neighborhood environmental factors linked to hospitalizations of older people for viral lower respiratory tract infections in Spain: a case-crossover study

    Environmental Health: A Global Access Science Source, Vol. 21, Núm. 1

  3. Serological Biomarkers at Hospital Admission Are Not Related to Long-Term Post-COVID Fatigue and Dyspnea in COVID-19 Survivors

    Respiration, Vol. 101, Núm. 7, pp. 658-665

2021

  1. Recurring Severe Injection-Related Infections in People Who Inject Drugs and the Need for Safe Injection Sites in Madrid, Spain

    Open Forum Infectious Diseases, Vol. 8, Núm. 7

2020

  1. Epidemiological trend of hepatitis C-related liver events in Spain (2000–2015): A nationwide population-based study

    European Journal of Internal Medicine, Vol. 75, pp. 84-92

  2. Epidemiological trend of sepsis in patients with hospital admissions related to hepatitis C in Spain (2000–2015): A nationwide study

    Journal of Clinical Medicine, Vol. 9, Núm. 6

  3. Gender-based vulnerability in women who inject drugs in a harm reduction setting

    PLoS ONE, Vol. 15, Núm. 3

  4. The pandemyc score. An easily applicable and interpretable model for predicting mortality associated with COVID-19

    Journal of Clinical Medicine, Vol. 9, Núm. 10, pp. 1-10

2019

  1. HIV coinfection predicts failure of ledipasvir/sofosbuvir in treatment-naïve noncirrhotic patients with HCV genotype

    Open Forum Infectious Diseases, Vol. 6, Núm. 5

  2. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units

    International Journal of Drug Policy, Vol. 72, pp. 181-188

  3. National temporal trend analysis of infective endocarditis among patients infected with HIV in Spain (1997–2014): A retrospective study

    Journal of Clinical Medicine, Vol. 8, Núm. 8

2018

  1. Epidemiological trends of deep venous thrombosis in HIV-infected subjects (1997–2013): A nationwide population-based study in Spain

    European Journal of Internal Medicine, Vol. 48, pp. 69-74

  2. HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination

    PLoS ONE, Vol. 13, Núm. 10

  3. High HIV seroconversion rate in hepatitis C virus-infected drug users followed in a harm reduction unit: A lost opportunity for preexposure prophylaxis

    AIDS, Vol. 32, Núm. 9, pp. 1157-1163

  4. Trends in pulmonary embolism in patients infected with HIV during the combination antiretroviral therapy era in Spain: A nationwide population-based study

    Scientific Reports, Vol. 8, Núm. 1